‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England
Executive Summary
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
You may also be interested in...
Vertex Finally Inks Orkambi Deal In England
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
At Last: Vertex Strikes CF Deal In England
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.
Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi
The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.